Gossamer Bio, Inc. (GOSS)

Market Cap	309.13M
Revenue (ttm)	124.59M
Net Income (ttm)	-51.24M
Shares Out	227.30M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	696,002
Open	1.340
Previous Close	1.360
Day's Range	1.340 - 1.400
52-Week Range	0.662 - 1.550
Beta	1.86
Analysts	Strong Buy
Price Target	7.33 (+438.97%)
Earnings Date	Aug 11, 2025

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The compa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 8, 2019
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: GOSS
• Website: https://www.gossamerbio.com

Analyst Summary

According to 3 analysts, the average rating for GOSS stock is "Strong Buy." The 12-month stock price target is $7.33, which is an increase of 438.97% from the latest price.

Price Target

$7.33

(438.97% upside)

Analyst Consensus: Strong Buy